1. Scrip
  2. >>Therapy Areas

Tetraphase Bets On I.V. Eravacycline Rerun As Antibiotic Market Influx Looms

 
• By Lucie Ellis-Taitt

Tetraphase has been keeping its head down since a 2015 Phase III trial failure for its lead antibiotic drug eravacycline sliced around $1.3bn from the company's market cap – but 2017 will be a turnaround year, says CEO Guy Macdonald.

Guy Macdonald
Tetraphase CEO Guy Macdonald Has High Hopes For Lead Antibiotic Despite Past Failure • Source: Tetraphase Pharmaceuticals

After a disappointing late-stage setback for its lead antibiotic compound in September 2015, publicly traded Tetraphase Pharmaceuticals Inc. is back on track to get its first drug filed by the end of this year, CEO Guy Macdonald told Scrip in a recent interview.

"2016 was our year of getting things done after a setback the previous year," Macdonald said. He highlighted that the company is expecting Phase III data in the third quarter for its lead compound, eravacycline, as an intravenous (I.V.) treatment for complicated intra-abdominal infections

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.